Pharmacological exposure and the development of drug resistance in HIV

Antiviral Therapy

Volumn 6, Issue SUPPL. 2, 2001, Pages 37-47

  Hoetelmans, R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RNA-DIRECTED DNA POLYMERASE; TREATMENT OUTCOME;

EID: 0034795624     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Deaths: Final data for 1998
2. Trends in mortality rates among reported Acquired Immune Deficiency (AIDS) case patients in New York City, 1990-1998
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Analysis of HIV-1 clinical trials: Statistical magic?
5. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
6. Outcome and predictors of failure of highly active antiretroviral therapy: One year follow-up of a cohort of human immunodeficiency type-1-infected persons
7. Effect of prior treatment and host genotype on response to highly active antiretroviral therapy in the multicenter AIDS cohort study (MACS)
8. Discordance between genotypic and phenotypic drug resistance in HIV-1 seropositive patients treated with two nucleoside analogues
9. Drug resistance and predicted virological responses to human immunodeficiency virus type 1 protease inhibitor therapy
10. Genotypic and phenotypic evidence of antiretroviral drug resistance among drug-naive persons recently diagnosed with HIV-1, USA, 1997-1999
11. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: A further obstacle to eradication
12. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples
13. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
14. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents
15. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection
16. Pharmacokinetics of the combination of nevirapine, nelfinavir and saquinavirhgc in HIV-infected patients (NELSANE study)
17. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
18. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients
19. Pharmacokinetic (PK) interactions between ritonavir (RTV) and amprenavir (APV) in healthy volunteers
20. Amprenavir (APV) plasma concentrations are dramatically increased by association with ritonavir (RTV) baby-doses in HIV-infected patients (pts): Possible combination with efavirenz (EFV)
21. Efficacy of the combination of ritonavir plus indinavir plus a nonnucleoside reverse transcriptase inhibitor in patients failing multiple antiretroviral regimens: Pharmacokinetic and resistance data (NIVELPROT study)
22. Ritonavir intensification of indinavir-containing antiretroviral regimens: The effect of increasing indinavir trough concentration and protease resistance on virological response
23. Modulation of saquinavir steady-state pharmacokinetics with 'baby' doses of ritonavir in healthy volunteers
24. Drug concentration heterogeneity facilitates the evolution of drug resistance
25. Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships
26. Indinavir concentrations and antiviral effect
27. HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1648, in human liver microsomes
28. Therapeutic drug monitoring of antiretrovirals: Ready for the clinic?
29. How will HIV therapeutic drug monitoring be used in clinical settings?
30. Antiretroviral drug resistance testing in adult with HIV infection
31. Therapeutic drug monitoring of antiretroviral agents
32. Sanctuary sites in HIV-1 infection
33. The limited value of therapeutic drug monitoring in HIV infection
34. min/IC ratio: False precision?
35. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
36. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient
37. Quantitative prediction of HIV-1 phenotypic resistance from genotypes: The virtual phenotype (Virtual Phenotype)
38. Both antiretroviral drug levels and drug resistance are associated with short-term virologic responses to subsequent drug regimens in CPCRA 046 (GART study)
39. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt A prospective multicentric randomized controlled trial: 12 Weeks results
40. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: Results from Athena
41. The promise of therapeutic drug monitoring in HIV infection
42. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection
43. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus
44. Concentrations of phosphorylated zidovudine (ZDV) in patients leukocytes do not correlate with ZDV dose or plasma concentrations
45. Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir and ritonavir
46. A 24-week, open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
47. Low plasma concentrations of indinavir are related to virological failure in HIV-1-infected patients on indinavir-containing triple therapy
48. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
49. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
50. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
51. Pharmacologic characteristics of indinavir, didanosine and stavudine in human immunodefificiency virus-infected children receiving combination therapy
52. Urological complaints in relation to indinivir plasma concentrations in HIV-infected patients
53. High prevalence of subclinical nephrotoxicity with indinavir
54. The effect of high-dose saquinavir on viral load an CD4+ T-cell counts in HIV-infected patients
55. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease
56. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
57. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
58. Decreased P-glycoprotein but unaltered multidrug resistance-associated protein in HIV patients
59. The role of P-glycoprotein in oral bioavailability, brain and fetal penetration of the HIV protease inhibitor saquinavir
60. Intracellular pharmacokinetics in HIV positive patients
61. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testis
62. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
63. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
64. Multiple-dose pharmacokinetics(PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in healthy volunteers
65. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
66. A randomized study comparing continued indinavir (800 mg tid) to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleosides analogues. The bid efficacy and safety trial (BEST)
67. Population pharmacokinetics of efavirenz in Phase II studies and relationship with efficacy
68. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
69. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection
70. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: The INCAS trial. Italy, the Netherlands, Canada and Australia study